NCI Committed to Increasing Minority Participation in Clinical Trials

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 4 No 7
Volume 4
Issue 7

BETHESDA, Md--Acting NCI Director Edward Sondik announced that the institute is committed to increasing participation of minorities in clinical trials. However, cancer researchers have had only limited success in this effort, he said.

BETHESDA, Md--Acting NCI Director Edward Sondik announced thatthe institute is committed to increasing participation of minoritiesin clinical trials. However, cancer researchers have had onlylimited success in this effort, he said.

Dr. Sondik's remarks were made at a meeting of a new coalition,the Intercultural Cancer Council, sponsored by Baylor Collegeof Medicine, the Susan G. Komen Breast Cancer Foundation, M.D.Anderson Cancer Center, Howard University Hospital, the AmericanCancer Society, and Kellogg Company.

Recent Videos
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Thomas Hope, MD, believes that an NRC initiative to update infiltration guidelines may organically address concerns that H.R. 2541 outlines.
Insurance and distance to a tertiary cancer center were 2 barriers to receiving high-quality breast cancer care, according to Rachel Greenup, MD, MPH.
4 experts are featured in this series.
4 experts are featured in this series.
Thomas Hope, MD, had not observed an adverse effect attributable to an infiltration across more than a decade of administering nuclear agents at UCSF.
Numerous clinical trials vindicating the addition of immunotherapy to first-line chemotherapy in SCLC have emerged over the last several years.
Two experts are featured in this series.
Two experts are featured in this series.
According to John Henson, MD, “What we need are better treatments to control the [brain] tumor once it’s detected.”
Related Content